The present investigation is focused on improving oral bioavailability of poorly soluble and lipophilic drugs, curcumin (CRM) and duloxetine (DXH), through the solid self-nanoemulsifying drug delivery system (S-SNEDDS) and identifying their potential against attenuation of NP in chronic constriction injury (CCI)–induced rats through the solid self-nanoemulsifying drug delivery system (S-SNEDDS). The optimized batch of S-SNEDDS reported was containing CRM and DXH (30 mg each), castor oil (20% w/w), tween-80 (40% w/w), transcutol-P (40% w/w), and syloid 244 FP (1 g). The high dose of each of naïve CRM (NCH), naïve DXH (NDH), physical mixture of DXH and CRM (C-NCM-DXH), S-SNEDDS-CRM (SCH), S-SNEDDS-DXH (SDH), and S-SNEDDS-CRM-DXH (C-SCH-SDH) was subjected for MTT assay. The developed formulations were subjected to pharmacokinetic studies and results showed about 8 to 11.06 and 2-fold improvement in oral bioavailability of CRM and DXH through S-SNEDDS. Furthermore, CCI-induced male Wistar rats were treated with SSNEDDS containing CRM and DXH, S-SNEDDS containing individual drug, individual naïve forms, and their combination from the day of surgery for 14 days and evaluated for behavioral at pre-determined time intervals. On the terminal day, animals were sacrificed to assess tissue myeloperoxidase, superoxide anion, protein, tumor necrosis factor-α, total calcium levels, and histopathological changes. Pronounced effect was observed in rats treated with S-SNEDDS containing both drugs with respect to rats receiving any of other treatments owing to enhanced oral bioavailability through S-SNEDDS. Therefore, it can be concluded that S-SNEDDS of both drugs and their coadministration can accelerate the prevention of NP.

本研究的重点是通过固体自纳米乳化药物递送系统（S-SNEDDS）改善难溶性和亲脂性药物，姜黄素（CRM）和度洛西汀（DXH）的口服生物利用度，并确定其对慢性NP衰减的潜力收缩性损伤（CCI）诱导的大鼠通过固体自纳米乳化药物递送系统（S-SNEDDS）。报告的S-SNEDDS的优化批次包含CRM和DXH（各30 mg），蓖麻油（20％w / w），tween-80（40％w / w），transcutol-P（40％w / w）和糖浆244 FP（1克）。高剂量的天真CRM（NCH），天真DXH（NDH），DXH和CRM的物理混合物（C-NCM-DXH），S-SNEDDS-CRM（SCH），S-SNEDDS-DXH（SDH），对S-SNEDDS-CRM-DXH（C-SCH-SDH）进行MTT分析。所开发的制剂进行了药代动力学研究，结果表明，通过S-SNEDDS，CRM和DXH的口服生物利用度提高了约8至11.06，并且提高了2倍。此外，自手术当天起，将CCI诱导的雄性Wistar大鼠用含有CRM和DXH的SSNEDDS，含有个别药物，个别初次使用的形式及其组合的S-SNEDDS处理，手术时间为14天，并在预定的时间间隔内评估其行为。在最后一天，处死动物以评估组织髓过氧化物酶，超氧阴离子，蛋白质，肿瘤坏死因子-α，总钙水平和组织病理学变化。由于通过S-SNEDDS提高的口服生物利用度，在接受包含两种药物的S-SNEDDS治疗的大鼠中，相对于接受任何其他治疗的大鼠，观察到了显着的效果。因此，